The Next Generation Weight Loss Injection – What You Need to Know

Published by Murrays Chemist | Harrow, UK

What is Retatrutide?

Retatrutide is a groundbreaking new weight loss drug currently in advanced clinical trials. Unlike existing GLP-1 medications like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro), Retatrutide works on three hormone pathways – GLP-1, GIP, and glucagon receptors. This triple-agonist mechanism may offer unprecedented weight loss outcomes compared to current injectable weight loss treatments.

Retatrutide is not yet licensed in the UK, but the hype is growing rapidly thanks to impressive trial results.

How Does Retatrutide Differ from Ozempic and Tirzepatide?

Clinical Evidence: Why Retatrutide Could Be a Game-Changer

In the 2023 Phase 2 trials published in The New England Journal of Medicine, patients on Retatrutide experienced up to 26% body weight loss over 48 weeks. This is significantly more than any other weight loss injection on the market.

Patients also showed improved insulin resistance, metabolic markers, and potential benefits for fatty liver disease and cardiovascular risk. Long-term studies are still underway.

👉 Source: NEJM Study on Retatrutide

When Will Retatrutide Be Available in the UK?

Retatrutide is currently undergoing Phase 3 clinical trials. Based on the timeline of other GLP/GIP medications, we expect:

• MHRA approval: Estimated late 2025 to early 2026

• Private UK availability: As early as 2026

• NHS rollout (if approved): Possibly 2027 or later

Murrays Chemist will closely monitor its progress and be among the first in Harrow to offer it once it becomes available.

Potential Side Effects and Considerations

Although Retatrutide appears safe in trials, the following side effects have been reported:

• Nausea and vomiting (dose-dependent, often mild)

• Diarrhoea or constipation

• Headaches

• Fatigue

• Rare risk of pancreatitis, thyroid concerns, or gallstones – similar to other GLP-1 therapies

Retatrutide may also increase heart rate, and its glucagon component raises questions about muscle loss vs. fat burning, which ongoing studies aim to clarify.

Is Retatrutide Right for You?

Retatrutide isn’t available just yet, but it could be an excellent future option for:

• Patients with obesity (BMI ≥30) or overweight (BMI ≥27 with comorbidities)

• People who haven’t responded well to semaglutide or tirzepatide

• Those with insulin resistance, PCOS, or fatty liver

At Murrays Chemist in Harrow, we already offer advanced, safe face-to-face weight loss programmes using GLP-1 medications, supported by monthly health checks, blood tests, and tailored support.

What To Do While You Wait

Until Retatrutide becomes available, we continue to support patients on:

• Wegovy / Ozempic (Semaglutide)

• Mounjaro (Tirzepatide)

• Lifestyle and diet coaching

• Monitoring of blood markers and body composition

Book a Weight Loss Consultation at Murrays Chemist

We offer in-person weight loss clinics for patients across Harrow, Wembley, Stanmore, and surrounding areas. Our clinical pharmacist-led service ensures you’re on the most appropriate treatment path based on your goals, medical history, and lab results.

Frequently Asked Questions

Q: Is Retatrutide better than Ozempic?
Early evidence suggests it may offer greater weight loss, but long-term outcomes are still under review.

Q: Will Retatrutide be available privately before the NHS?
Most likely yes – just like Wegovy and Mounjaro.

Q: Can I pre-register for Retatrutide at Murrays Chemist?
Yes, contact us to express interest and we’ll notify you when it becomes available.

Stay Informed

Follow Murrays Chemist on Facebook and Instagram for updates on the latest obesity treatments, wellness services, and UK drug approvals.